Protara Therapeutics
TARA | NASDAQ
$2.38
-$0.15 (-5.93%)
At close: Nov 16, 2026, 4:00 PM ET
$2.42
+$0.04 (+1.68%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.93%
(1D)No price chart data available for 1D timeframe.
Rating
24.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #943/1021 (Top 92%)
Key Statistics
Market Data
Market Cap $146.54M
1D Range
2.36 2.52
52W Range
2.13 7.56
Valuation (TTM)
PE -1.70
PB 1.04
EV/EBITDA -0.28
Valuation (NTM)
Forward PE N/A
Forward PEG -0.20
Price Target $12.00
Cash Flow
FCF Yield -50.0%
SBC Adj. FCF Yield -53.6%
SBC Impact -7.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 37.7% |
27.8%
FCF 3Y | 5Y -36.2% |
-23.7%
Returns
ROA -50.1%
ROE -46.1%
ROIC -59.4%
Financial Health
Net Cash
$124.61M
Current Ratio 9.01
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle...
Sector Healthcare
Industry Biotechnology
Employees 46
IPO Date Oct 22, 2014
Website www.protaratx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$12.00
Upside
+404.20%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove TARA